Senti Biosciences Q2 EPS $(0.42) Beats $(0.48) Estimate, Sales $937.00K Beat $500.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Senti Biosciences reported Q2 losses of $(0.42) per share, beating the analyst consensus estimate of $(0.48) by 12.5%. The company's quarterly sales were $937.00K, surpassing the analyst consensus estimate of $500.00K by 87.4%. However, this represents a 31.00% decrease in sales compared to the same period last year.
August 11, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Senti Biosciences reported better than expected Q2 results with EPS and sales beating estimates. However, sales decreased by 31% compared to last year.
While Senti Biosciences beat Q2 estimates, the decrease in sales compared to last year might concern investors. This mixed result could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100